Abstract
In the last years it has been proposed that the antidepressant action is mediated not only by changes in monoamine levels but also in association with modifications involving cell proliferation and plasticity in some brain limbic areas as hippocampus, and also frontal cortex and amygdala. This leads to the merging of the classic “monoaminergic hypothesis of depression”, with the newer “neurotrophic hypothesis of depression”. Here we review two important signaling pathways: the Wnt/β-catenin pathway —implicated in cellular proliferation and synaptic plasticity— that is downregulated in major depression and upregulated after antidepressant treatment; and the mTOR pathway —controling synaptic plasticity— recently related to present disrupted functioning in major depression, and as the target of some drugs with fast-acting potential antidepressant action. These pieces of evidences are confirmed in a variety of animal models of depression and are predictive of antidepressant actions. We also review the role of another two important neurotrophic factors: brain derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) that mediate the antidepressant effects. All of the above intracellular pathways interact by a crosstalk mediated by Akt, a key regulator molecule that may underlie the fine tuning between proliferative and neuroplasticity changes induced by antidepressant drugs.
Keywords: β-catenin, GSK-3β, mTOR, BDNF, synaptic plasticity, neurogenesis, antidepressant drugs.
Current Pharmaceutical Design
Title:Signaling Pathways Involved in Antidepressant-Induced Cell Proliferation and Synaptic Plasticity
Volume: 20 Issue: 23
Author(s): Fuencisla Pilar-Cuellar, Rebeca Vidal, Alvaro Díaz, Elena Castro, Severiano dos Anjos, Veronica Vargas, Beatriz Romero and Elsa M. Valdizan
Affiliation:
Keywords: β-catenin, GSK-3β, mTOR, BDNF, synaptic plasticity, neurogenesis, antidepressant drugs.
Abstract: In the last years it has been proposed that the antidepressant action is mediated not only by changes in monoamine levels but also in association with modifications involving cell proliferation and plasticity in some brain limbic areas as hippocampus, and also frontal cortex and amygdala. This leads to the merging of the classic “monoaminergic hypothesis of depression”, with the newer “neurotrophic hypothesis of depression”. Here we review two important signaling pathways: the Wnt/β-catenin pathway —implicated in cellular proliferation and synaptic plasticity— that is downregulated in major depression and upregulated after antidepressant treatment; and the mTOR pathway —controling synaptic plasticity— recently related to present disrupted functioning in major depression, and as the target of some drugs with fast-acting potential antidepressant action. These pieces of evidences are confirmed in a variety of animal models of depression and are predictive of antidepressant actions. We also review the role of another two important neurotrophic factors: brain derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF) that mediate the antidepressant effects. All of the above intracellular pathways interact by a crosstalk mediated by Akt, a key regulator molecule that may underlie the fine tuning between proliferative and neuroplasticity changes induced by antidepressant drugs.
Export Options
About this article
Cite this article as:
Pilar-Cuellar Fuencisla, Vidal Rebeca, Díaz Alvaro, Castro Elena, Anjos dos Severiano, Vargas Veronica, Romero Beatriz and Valdizan M. Elsa, Signaling Pathways Involved in Antidepressant-Induced Cell Proliferation and Synaptic Plasticity, Current Pharmaceutical Design 2014; 20 (23) . https://dx.doi.org/10.2174/13816128113196660736
DOI https://dx.doi.org/10.2174/13816128113196660736 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Erythropoietin: A Neuroprotective Agent in Cerebral Hypoxia, Neurodegeneration, and Epilepsy
Current Pharmaceutical Design Ion Channels as Medicinal Targets of Biological Toxins: The Impact of Automated Patch-Clamp Electrophysiology
Current Topics in Medicinal Chemistry Synthesis and Anticonvulsant Activity of Some Novel Semicarbazone Containing Benzoxazole: Pharmacophore Model Study
Current Bioactive Compounds Therapeutic Application of Histone Deacetylase Inhibitors for Stroke
Central Nervous System Agents in Medicinal Chemistry Recent Developments in Deception Research
Current Psychiatry Reviews Synthesis and Anticonvulsant Activity of N-(trans)- 3-phenylprop-2-en-1-yl (Cinnamyl) Derivatives of Aminoalkanols
Letters in Drug Design & Discovery Editorial [Hot Topic: Adenosine-Based Modulation of Brain Activity (Guest Editor: DETLEV BOISON)]
Current Neuropharmacology Galanin: A Novel Therapeutic Target for Depression, Anxiety Disorders and Drug Addiction?
CNS & Neurological Disorders - Drug Targets Antipsychotic Medication Adherence and Satisfaction Among Palestinian People with Schizophrenia
Current Clinical Pharmacology Neuroimaging of Gut Nutrient Perception
Current Pharmaceutical Design Extracellular Vesicles in Glioblastoma: Role in Biological Processes and in Therapeutic Applications
Current Cancer Drug Targets Efficacy, Duration and Timing of Withdrawal of Prophylactic Treatment with Antiepileptic Drugs in Neurosurgical Conditions
Current Pharmaceutical Design CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Reverse Iontophoretic Extraction of Gabapentin: A Mechanistic Study
Current Drug Delivery Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology Occurrence of DAT1 (VNTR) Polymorphism in Individuals with HIV Infection
Current Pharmacogenomics and Personalized Medicine Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
Current Pharmaceutical Design Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Supplements, Diets and Other Complementary and Alternative Interventions in Adolescent Mental Health
Adolescent Psychiatry